Immunotherapy and biomarkers: Developments in Combination Therapy for Cancer
Over the past few years, increasing evidence has supported the role of biomarkers in immunotherapy. Combination therapy - the use of a combination of products or modalities to treat cancer - is one way to use biomarkers to reveal the...
4 years agoImmunotherapy and biomarkers: Developments in Combination Therapy for Cancer
Over the past few years, increasing evidence has supported the role of biomarkers in immunotherapy. Combination therapy - the use of a combination of products or modalities to treat cancer - is one way to use biomarkers to reveal the...
4 years ago
Weekly News Round-up – 1/4/21
In the news this week, GSK agrees to support NOVAVAX vaccine production to meet UK targets. In other news, Amgen Inc. confirms its agreement to acquire Rodeo Therapeutics, and COVID-19 vaccine production is boosted by expansions in production with BioNtech...
4 years agoWeekly News Round-up – 1/4/21
In the news this week, GSK agrees to support NOVAVAX vaccine production to meet UK targets. In other news, Amgen Inc. confirms its agreement to acquire Rodeo Therapeutics, and COVID-19 vaccine production is boosted by expansions in production with BioNtech...
4 years ago
The Challenges of Drug Delivery: An Interview With Prof. Afzal R Mohammed
Conventional drug delivery methods, such as oral and systemic administration, face issues of optimisation, and present certain challenges for physicians. Proventa spoke to Professor Afzal Ur-Rahman Mohammed, Head of Pharmaceutical Sciences at Aston University Pharmacy School, about these challenges, and...
4 years agoThe Challenges of Drug Delivery: An Interview With Prof. Afzal R Mohammed
Conventional drug delivery methods, such as oral and systemic administration, face issues of optimisation, and present certain challenges for physicians. Proventa spoke to Professor Afzal Ur-Rahman Mohammed, Head of Pharmaceutical Sciences at Aston University Pharmacy School, about these challenges, and...
4 years ago
Evaluating methods targeting Protein-Protein Interactions: A Clinical Demand
Protein-protein interactions (PPIs) are becoming increasingly relevant in the pathology of many diseases, including cancer. The issue, however, is developing an effective way of targeting them. The latest advancements in methods targeting PPIs are designed to overcome the challenges limiting...
4 years agoEvaluating methods targeting Protein-Protein Interactions: A Clinical Demand
Protein-protein interactions (PPIs) are becoming increasingly relevant in the pathology of many diseases, including cancer. The issue, however, is developing an effective way of targeting them. The latest advancements in methods targeting PPIs are designed to overcome the challenges limiting...
4 years ago
Weekly News Round-Up – 26/3/21
In the news this week, reports urge pharmaceutical companies to exploit the benefits of synthetic data in clinical trials. In other news, FDA fears over the safety of tanezumab compromises approval for the Pfizer/Lilly pain drug, and the COSMIC database...
4 years agoWeekly News Round-Up – 26/3/21
In the news this week, reports urge pharmaceutical companies to exploit the benefits of synthetic data in clinical trials. In other news, FDA fears over the safety of tanezumab compromises approval for the Pfizer/Lilly pain drug, and the COSMIC database...
4 years ago
Optimising Paediatric Studies in Clinical Drug Development
Drug development in the world of paediatric medicine is hitting a wall. Without developing new strategies, patient recruitment and retention will continue to plummet and jeopardise lives. Innovative changes to clinical trial design and learning about patient incentives have opened...
4 years agoOptimising Paediatric Studies in Clinical Drug Development
Drug development in the world of paediatric medicine is hitting a wall. Without developing new strategies, patient recruitment and retention will continue to plummet and jeopardise lives. Innovative changes to clinical trial design and learning about patient incentives have opened...
4 years agoInterested?
Reserve your space
